“SCENESSE®: Commercialization of a First-In-Class NCE”

In Clinical Development, Featured on App, Market Access, Orphan Drug Congress by Freya Smale

Nicoletta Muner of Clinuvel Pharmaceuticals Ltd.   joined us for World Orphan Drug Congress USA 2015 to present about ‘ SCENESSE®    :Commercialization of a First-In-Class NCE’ 
Download her presentation now to understand more about:

  • Scenesse Clincial Program
  • Erythropoietic Protoporphyria (EPP)
  • EPP Clinical Development and Expanded Access
  • EMA Evaluation (Centralised Procedur)
…and much more!
Get your copy here!
To find out more about  SCENESSE®   , attend  World Orphan Drug Congress USA 2016 April 20-22  in Washington, DC.